Catalyst
Slingshot members are tracking this event:
Fibrocell's (FCSC ) Orphan Drug FCX-013, a gene therapy treatment for localized scleroderma. granted Rare Pediatric Disease Designation by FDA
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FCSC | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 12, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Orphan Drug, Gene Therapy, Scleroderma, Fcx-013, Rare Pediatric Disease Designation
